Legend, a smaller biotech, partnered with J&J, the leader in multiple myeloma. This symbiotic relationship allowed Legend to focus on its scientific and manufacturing strengths while leveraging J&J's massive commercial scale and deep market expertise to achieve global reach and market leadership.
Legend Biotech committed massive capital to build its world-class cell therapy manufacturing network *after* gaining high conviction from its clinical data. This data-first approach de-risked the decision to invest heavily, ensuring that manufacturing capacity was built for a product with a high probability of success.
To avoid bureaucratic slowdowns as it scales, Legend Biotech maintains its nimble "startup" culture by constantly focusing the team on patient needs. This patient-centricity, combined with efficient leadership decision-making, ensures the company operates with speed and purpose despite its large size.
Legend's R&D model leverages early-stage, investigator-led trials in China to generate clinical data rapidly. This approach allows the company to make quicker, more informed decisions about which programs to advance into larger, global development, creating a more efficient and data-driven pipeline.
To scale autologous CAR-T therapies, Legend Biotech is pursuing a three-part strategy: increasing the number of authorized centers, enabling community and regional hospitals (not just academic hubs) to administer treatment, and promoting outpatient administration to reduce the burden on hospital beds.
The high capital cost of autologous CAR-T manufacturing creates a moat for incumbents like Legend. Consequently, future investment will likely flow towards next-generation platforms like in vivo CAR-T, which promises an "off-the-shelf" solution that eliminates complex external manufacturing and patient pre-conditioning.
The next wave of cell therapy, in vivo CAR-T, aims to turn the patient's body into the manufacturing plant. This eliminates the need for apheresis, external manufacturing, and lymphodepletion, effectively creating an off-the-shelf biologic that can be administered in community practices with no wait time.